Nevro (NYSE:NVRO) Releases Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Nevro (NYSE:NVRO) announced its earnings results on Tuesday. The medical equipment provider reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.15, Zacks reports. Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%.

Nevro Trading Up 0.3 %

Nevro stock traded up $0.02 during midday trading on Tuesday, reaching $5.74. The stock had a trading volume of 627,761 shares, compared to its average volume of 657,294. The stock’s 50-day simple moving average is $4.82 and its 200 day simple moving average is $4.93. Nevro has a twelve month low of $3.17 and a twelve month high of $15.98. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.76 and a current ratio of 5.02. The stock has a market capitalization of $214.90 million, a PE ratio of -3.03 and a beta of 0.94.

Wall Street Analyst Weigh In

A number of analysts recently commented on NVRO shares. Morgan Stanley cut Nevro from an “equal weight” rating to an “underweight” rating and dropped their price objective for the stock from $9.00 to $4.00 in a research report on Monday, December 2nd. Canaccord Genuity Group lifted their price target on shares of Nevro from $4.00 to $5.85 and gave the stock a “hold” rating in a report on Friday, February 7th. Piper Sandler raised shares of Nevro from a “neutral” rating to an “overweight” rating and reduced their price objective for the company from $6.00 to $5.85 in a research note on Friday, February 7th. Robert W. Baird lifted their target price on shares of Nevro from $5.00 to $6.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 12th. Finally, Jefferies Financial Group upgraded Nevro from an “underperform” rating to a “hold” rating and boosted their price target for the company from $4.50 to $5.85 in a report on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $6.43.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.